NO20004788L - Kombinasjon for behandling av alkohol- og medikamentavhengighet inneholdende en opoidantagonist og en NMDA- reseptorkompleksmodulator - Google Patents

Kombinasjon for behandling av alkohol- og medikamentavhengighet inneholdende en opoidantagonist og en NMDA- reseptorkompleksmodulator

Info

Publication number
NO20004788L
NO20004788L NO20004788A NO20004788A NO20004788L NO 20004788 L NO20004788 L NO 20004788L NO 20004788 A NO20004788 A NO 20004788A NO 20004788 A NO20004788 A NO 20004788A NO 20004788 L NO20004788 L NO 20004788L
Authority
NO
Norway
Prior art keywords
nmda receptor
receptor complex
alcohol
treatment
combination
Prior art date
Application number
NO20004788A
Other languages
English (en)
Other versions
NO319313B1 (no
NO20004788D0 (no
Inventor
Martine Daoust
Yves Bonhomme
Philippe Durbin
Original Assignee
Lipha
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lipha filed Critical Lipha
Publication of NO20004788D0 publication Critical patent/NO20004788D0/no
Publication of NO20004788L publication Critical patent/NO20004788L/no
Publication of NO319313B1 publication Critical patent/NO319313B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO20004788A 1998-03-26 2000-09-25 Anvendelse av en synergistisk kombinasjon av en opioidantagonist og en NMDA reseptorkompleksmodulator for behandling av alkoholavhengighet NO319313B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP98400723A EP0945133A1 (en) 1998-03-26 1998-03-26 Combination for the treatment of alcohol and drug dependence containing an opioid antagonist and a NMDA receptor complex modulator
PCT/EP1999/002337 WO1999048500A1 (en) 1998-03-26 1999-03-26 Combination for the treatment of alcohol and drug dependence containing an opioid antagonist and a nmda receptor complex modulator

Publications (3)

Publication Number Publication Date
NO20004788D0 NO20004788D0 (no) 2000-09-25
NO20004788L true NO20004788L (no) 2000-11-24
NO319313B1 NO319313B1 (no) 2005-07-11

Family

ID=8235311

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20004788A NO319313B1 (no) 1998-03-26 2000-09-25 Anvendelse av en synergistisk kombinasjon av en opioidantagonist og en NMDA reseptorkompleksmodulator for behandling av alkoholavhengighet

Country Status (18)

Country Link
US (1) US6512009B1 (no)
EP (2) EP0945133A1 (no)
KR (1) KR20010034678A (no)
AT (1) ATE230993T1 (no)
AU (1) AU758569B2 (no)
BR (1) BR9909138A (no)
CA (1) CA2325739C (no)
CZ (1) CZ296367B6 (no)
DE (1) DE69904922T2 (no)
DK (1) DK1063995T3 (no)
ES (1) ES2190205T3 (no)
HK (1) HK1032542A1 (no)
HU (1) HU226555B1 (no)
NO (1) NO319313B1 (no)
PL (1) PL193241B1 (no)
RU (1) RU2226107C2 (no)
SK (1) SK284623B6 (no)
WO (1) WO1999048500A1 (no)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8052982B2 (en) 1998-07-20 2011-11-08 Peptech Animal Health Pty Limited Bioimplant formulation comprising lecithin and stearin
BR9912275A (pt) * 1998-07-20 2001-04-17 Peptech Ltd Formulação de bioimplante
WO2001052851A1 (en) * 2000-01-22 2001-07-26 Albert Shulman Methods for the treatment of substance abuse
EP1262196A3 (en) * 2001-05-23 2002-12-18 Pfizer Products Inc. Combination of a monoamine reuptake inhibitor and an opioid antagonist for use in alcoholism and alcohol dependence
DE10129265A1 (de) * 2001-06-18 2003-01-02 Hf Arzneimittelforsch Gmbh Wirkstoff-Kombination zur medikamentösen Sucht- oder Rauschmitteltherapie
ES2187288B1 (es) * 2001-09-24 2004-09-16 Garbil Pharma Investigacion Chile Ltda Aminas como agentes anti-alcoholismo.
ES2665999T3 (es) 2002-05-31 2018-04-30 Titan Pharmaceuticals, Inc. Dispositivo polimérico implantable para la liberación sostenida de buprenorfina
AU2003299659A1 (en) * 2002-12-13 2004-07-09 Durect Corporation Oral drug delivery system comprising high viscosity liquid carrier materials
EP1572164A2 (en) * 2002-12-18 2005-09-14 Pain Therapeutics, Inc. Oral dosage forms with therapeutically active agents in controlled release cores and immediate release gelatin capsule coats
PL1610791T3 (pl) 2003-03-31 2011-07-29 Titan Pharmaceuticals Inc Wszczepialne urządzenie polimerowe do przedłużonego uwalniania agonisty dopaminy
CA2526101A1 (en) * 2003-05-30 2004-12-23 Titan Pharmaceuticals, Inc. Implantable polymeric device for sustained release of nalmefene
US20070099947A1 (en) * 2005-11-03 2007-05-03 Alkermes, Inc. Methods and compositions for the treatment of brain reward system disorders by combination therapy
US20100041689A1 (en) * 2006-12-19 2010-02-18 University Of Virginia Patent Foundation Combined Effects of Topiramate and Ondansetron on Alcohol Consumption
JP2011506318A (ja) * 2007-12-06 2011-03-03 デュレクト コーポレーション 経口医薬製剤
KR20100127799A (ko) 2008-02-28 2010-12-06 유니버시티 오브 버지니아 페이턴트 파운데이션 세로토닌 운반체 유전자 및 알콜중독의 치료
US20100260844A1 (en) 2008-11-03 2010-10-14 Scicinski Jan J Oral pharmaceutical dosage forms
AU2011274355B2 (en) 2010-07-02 2016-10-27 University Of Virginia Patent Foundation Molecular genetic approach to treatment and diagnosis of alcohol and drug dependence
EP3045173A3 (en) 2011-09-09 2016-09-14 The University of Virginia Patent Foundation Molecular genetic approach to treatment and diagnosis of alcohol and drug dependence
RU2476209C1 (ru) * 2012-02-29 2013-02-27 Станислав Анатольевич Кедик Имплантируемое лекарственное средство на основе налтрексона для лечения пациентов, зависимых от алкоголя или опиатов
CA2905131A1 (en) 2013-03-15 2014-09-18 Durect Corporation Compositions with a rheological modifier to reduce dissolution variability
GB201308440D0 (en) * 2013-05-10 2013-06-19 Dalgleish Angus Therapeutic
WO2023023038A1 (en) * 2021-08-17 2023-02-23 Yale University Treatment compositions and methods

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997033581A1 (en) * 1996-03-13 1997-09-18 Yale University Smoking cessation treatments using naltrexone and related compounds

Also Published As

Publication number Publication date
DE69904922T2 (de) 2004-01-08
WO1999048500A1 (en) 1999-09-30
NO319313B1 (no) 2005-07-11
EP0945133A1 (en) 1999-09-29
AU3522699A (en) 1999-10-18
RU2226107C2 (ru) 2004-03-27
NO20004788D0 (no) 2000-09-25
CZ296367B6 (cs) 2006-02-15
EP1063995A1 (en) 2001-01-03
EP1063995B1 (en) 2003-01-15
KR20010034678A (ko) 2001-04-25
ES2190205T3 (es) 2003-07-16
CZ20003525A3 (cs) 2001-04-11
DE69904922D1 (de) 2003-02-20
HUP0101546A3 (en) 2002-10-28
ATE230993T1 (de) 2003-02-15
CA2325739C (en) 2007-05-15
PL343069A1 (en) 2001-07-30
SK284623B6 (sk) 2005-08-04
AU758569B2 (en) 2003-03-27
CA2325739A1 (en) 1999-09-30
HU226555B1 (en) 2009-03-30
HK1032542A1 (en) 2001-07-27
HUP0101546A2 (hu) 2001-09-28
US6512009B1 (en) 2003-01-28
DK1063995T3 (da) 2003-03-10
SK14282000A3 (sk) 2001-05-10
PL193241B1 (pl) 2007-01-31
BR9909138A (pt) 2000-12-05

Similar Documents

Publication Publication Date Title
NO20004788L (no) Kombinasjon for behandling av alkohol- og medikamentavhengighet inneholdende en opoidantagonist og en NMDA- reseptorkompleksmodulator
ES2181055T3 (es) Formulaciones galenicas que contienen antagonistas de opiaceos.
DK0812195T3 (da) Farmaceutisk sammensætning til piperidinoalkanolforbindelser
EE9700241A (et) Farmatseutiline kompositsioon transdermaalseks manustamiseks
HUP9701694A3 (en) Indolinone derivatives for the treatment of disease, use thereof, pharmaceutical compositions containing these compounds
DK0747050T4 (da) Farmaceutiske sammensætninger, der indeholder irbesartan
PL326203A1 (en) (methylsulphonyl)phenyl-2-(5)-furanones as cox-2 inhibitors
NO973479L (no) Substituerte heterosykliske forbindelser, fremgangsmåte for fremstilling og farmasöytiske blandinger inneholdende samme
IL116673A (en) Stable oral pharmaceutical composition containing an acid labile benzimidazole
DZ2614A1 (fr) Compositions pharmaceutiques topiques contenant des dérivés de résorcinol.
DE69634053D1 (de) Oral anzuwendende Arzneizusammensetzung enthaltend 2-Methyl-thienobenzodiazepin
ATE339406T1 (de) Chinazoline verbindungen als heilmittel
SE9904505D0 (sv) Novel compounds
ES2171723T3 (es) 3,4-diaril-2-hidroxi-2,5-dihidrofuranos como profarmacos de inhibidores de cox-2.
AU1549500A (en) Use of n-substituted azaheterocyclic compounds for the manufacture of a pharmaceutical composition for the treatment of indications related to angiogenesis
NO20021898D0 (no) Farmasöytisk sammensetning inneholdende ciclesonid for applikasjon til mukosa
IL145645A0 (en) N-(2-phenyl-4-amino-butyl)-1-naphthamides as neurokinin-1 receptor antagonists
MX9708394A (es) Composicion farmaceutica que contiene clorhidrato de tiagabina y el proceso para su preparacion.
ATE400563T1 (de) Neue neurokinin-antagonisten zum gebrauch als arzneimittel
ES2188908T3 (es) Derivados de cis-3,4-cromano utiles para la prevencion o tratamiento de sindromes relacionados con el estrogenos.
DK0758312T3 (da) Substituerede fusionerede og broforbundne bicykliske forbindelser som terapeutiske midler
MX9709453A (es) Composicion farmaceutica oral de compuestos de piperidinoalcanol en forma de solucion.
ITMI950958A0 (it) Composizioni farmaceutiche per il trattamento della alcol-dipendenza
IT1269545B (it) Derivati idantoinici
SE9803277D0 (sv) Novel compounds

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees